Migraine patch developer Zosano Pharma sold in bankruptcy court to Emergex for $1 million - Silicon Valley Business Journal

日本 ニュース ニュース

Migraine patch developer Zosano Pharma sold in bankruptcy court to Emergex for $1 million - Silicon Valley Business Journal
日本 最新ニュース,日本 見出し
  • 📰 svbizjournal
  • ⏱ Reading Time:
  • 35 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 59%

An East Bay company's 16-year goal to deliver drugs through tiny needles on an adhesive patch comes to an end in bankruptcy court.

Nearly 30 months ago, Zosano Pharma Corp. won a date for an FDA decision on its microneedle-packed patch to soothe migraines. Last week, the company closed its sale out of bankruptcy court for $1 million.

In addition to the sale price, Emergex could pay up to $250,000 to cover the dismantling and removal of Zosano assets. Zosano's program used a proprietary formulation of the drug for people who have five or more migraines a month, showing through clinical trials that its product could provide migraine pain relief within 30 minutes.

But when that time rolled around, the FDA rejected the drug-device, citing inconsistent exposure levels of the drug in five of 774 patients who received different lots of the drug in clinical trials. The agency also noted inadequate"pharmacokinetic bridging" between drug lots that made interpretation of some safety data unclear.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

svbizjournal /  🏆 334. in US

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Moderna booster application goes to FDA for authorizationModerna booster application goes to FDA for authorizationThis updated formulation is a bivalent vaccine that will combine the original vaccine with one that targets omicron sublineages BA.4 and BA.5.
続きを読む »

Trump staffers pushed unproven COVID treatment at FDA: PanelTrump staffers pushed unproven COVID treatment at FDA: PanelOfficials in the Trump White House tried to pressure U.S. health experts into reauthorizing a discredited COVID-19 treatment.
続きを読む »

Moderna booster application goes to FDA for authorizationModerna booster application goes to FDA for authorizationThis updated formulation is a bivalent vaccine that will combine the original vaccine with one that targets omicron sublineages BA.4 and BA.5.
続きを読む »

Moderna booster application goes to FDA for authorizationModerna booster application goes to FDA for authorizationThis updated formulation is a bivalent vaccine that will combine the original vaccine with one that targets omicron sublineages BA.4 and BA.5.
続きを読む »

FDA Plans To Authorize Updated Covid Boosters Around Labor DayFDA Plans To Authorize Updated Covid Boosters Around Labor DayThe Food and Drug Administration plans to authorize updated versions of Pfizer-BioNTech’s and Moderna’s Covid boosters around Labor Day, NBC News reported, citing two people familiar with the discussions. The Biden administration is preparing to distribute the updated booster shots to teenagers and adults as part of its fall booster campaign. Both Pfizer’s and Moderna’s reformulated shots target the BA.4…
続きを読む »



Render Time: 2025-03-04 21:38:00